Personalis, Inc. (PSNL) Stock Analysis and Metrics

Personalis

NASDAQ: PSNL

$15.05 ▲ +0.98 (+6.97%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.44 Bn

P/E-101.05

P/S22.27

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)879,000.00

Revenue Growth (1y) (Qtr)-24.91

Add ratio to table…

About

Personalis, Inc. develops markets and sells advanced cancer genomic testing services. The company operates in the precision oncology diagnostics industry providing tumor informed liquid biopsy tests comprehensive tumor profiling assays immuno oncology tissue based tests and whole exome and genome sequencing services for diagnostics companies and population sequencing initiatives.

Personalis, Inc. generates revenue primarily from the sale of its cancer genomic testing services to pharmaceutical and biopharmaceutical companies diagnostics companies universities non profits government entities and cancer patients. The company offers NeXT Personal Dx for minimal residual disease detection and recurrence monitoring NeXT Dx for comprehensive tumor profiling ImmunoID NeXT for immuno oncology tissue based analysis whole exome sequencing for diagnostic partners and whole genome sequencing for population sequencing initiatives. Revenue also stems from collaborative agreements such as the co commercialize arrangement with Tempus and from Medicare reimbursement for certain indications.

The company operates through the following segments.

• The Advanced Cancer Genomic Testing Services segment provides tumor informed liquid biopsy testing for minimal residual disease detection and recurrence monitoring through the NeXT Personal Dx assay which includes a Real Time Variant Tracker feature for reporting resistance associated and targetable mutations. The segment also offers NeXT Dx a comprehensive tumor profiling test that analyzes exome and transcriptome to support therapy selection and clinical trial identification. Additionally it supplies ImmunoID NeXT a tissue based test that combines exome and transcriptome data to characterize the tumor microenvironment and identify neoantigens for personalized immunotherapy. The segment further delivers whole exome sequencing services for diagnostic companies and whole genome sequencing services for population sequencing initiatives. All testing is performed in a CLIA certified CAP accredited high complexity laboratory located in Fremont California.

Personalis, Inc. competes in the cancer diagnostics market against companies such as Adela Inc Caris Life Sciences Inc DELFI Diagnostics Inc Exact Sciences Corporation Foresight Diagnostics Inc Foundation Medicine Inc GRAIL Inc Guardant Health Inc Haystack Oncology Inc Laboratory Corporation of America Holdings MedGenome Inc Myriad Genetics Inc Natera NeoGenomics Inc Predicine Inc SAGA Diagnostics AB and Veracyte Inc. The company differentiates itself through its ultrasensitive MRD detection capability that can identify cancer recurrence months before imaging its comprehensive genomic data reporting its high quality results and its responsive customer service. These strengths allow Personalis to gain traction with pharmaceutical partners seeking reliable biomarkers and with clinicians aiming to guide treatment decisions.

Personalis, Inc. serves a diverse customer base that includes global pharmaceutical and biopharmaceutical companies diagnostics companies universities non profits government entities and individual cancer patients. Specific customers that have contributed significant revenue include Moderna the VA MVP Natera and Tempus. The company also collaborates with numerous academic medical centers such as Cancer Research UK University College London the Francis Crick Institute Institut Curie the Royal Marsden Vall d'Hebron Institute of Oncology the University of California San Diego Duke University Vanderbilt University Johns Hopkins University Dana Farber Cancer Institute the University of Texas M D Anderson Cancer Center University Medical Center Hamburg Eppendorf Criterium the Academic Breast Cancer Consortium Yale Cancer Center Aarhus University British Columbia Cancer and University Health Network.

Investment Thesis

▲ Bull case

Personalis is uniquely positioned to capture disproportionate growth in the rapidly expanding MRD market through its clinically validated ultrasensitive technology, which detects cancer recurrence at single-digit parts-per-million levels—a sensitivity threshold that competitors cannot match and that is becoming a clinical necessity rather than a technical advantage. The company's recent Medicare coverage expansions for immunotherapy monitoring in late-stage solid tumors and neoadjuvant therapy monitoring in breast cancer represent critical inflection points that will drive immediate reimbursement acceleration, particularly as these indications cover large patient populations with high unmet needs for real-time treatment response monitoring. These coverage wins are not isolated events but validate the core thesis that NeXT Personal's ability to distinguish true disease burden from pseudoprogression in immunotherapy settings and detect early molecular response in neoadjuvant scenarios addresses fundamental limitations of current standard-of-care diagnostics, creating a durable moat that will support ASP expansion and margin recovery as volume shifts from unreimbursed to reimbursed testing.
The biopharma MRD partnership pipeline is demonstrating strong conversion momentum that remains underappreciated by the market, with committed trials expected to drive the majority of the $20 million to $21 million in full-year biopharma MRD revenue in the second half of 2026, supported by a growing backlog of prospective projects extending beyond 12 months that provides multi-year visibility. Unlike transient diagnostic sales, biopharma MRD engagements are inherently sticky due to the integration of NeXT Personal into clinical trial protocols as a primary endpoint biomarker, creating predictable, multi-year revenue streams as large oncology trials progress through enrollment and follow-up phases. This structural shift toward biopharma adoption is being driven by the irreplaceable need for high-resolution tools to de-risk next-generation therapies, a trend that will persist regardless of near-term reimbursement turbulence and positions Personalis as an indispensable partner in oncology drug development rather than merely a test vendor.
Clinical adoption metrics reveal a powerful inflection point in physician behavior and market expansion that transcends seasonal variability, with over 1,000 ordering physicians in Q1 2026 representing not just geographic breadth but deepening penetration within existing accounts, where retention exceeds 98% and physicians are progressively increasing test utilization as they build confidence in the technology's clinical utility. The real-world evidence showing 40% of positive detections occur in the ultrasensitive range below 100 parts per million across 14 cancer types provides irrefutable proof that conventional MRD tests are missing critical early recurrence signals, creating a self-reinforcing cycle where physicians who adopt NeXT Personal for its sensitivity become advocates who drive broader adoption within their networks—a dynamic that is particularly potent in community oncology settings where word-of-mouth validation outweighs traditional sales efforts and supports sustainable volume growth toward the 43,000 to 45,000 test annual target.
The company's strategic investment in the Variant Tracker module represents a hidden catalyst that extends NeXT Personal beyond static MRD detection into dynamic tumor evolution monitoring, addressing a critical unmet need in precision oncology by enabling physicians to track resistance variant emergence and therapy-induced biological changes in real time—capabilities that directly support adaptive treatment strategies and are increasingly valued in both clinical and biopharma contexts. Early positive feedback on this feature, combined with its presentation at ASCO, suggests it will become a key differentiator that commands premium pricing and expands the total addressable market into therapy monitoring and resistance prediction, areas where current competitors lack comparable functionality and where reimbursement pathways are likely to emerge faster due to clear health economic benefits in avoiding ineffective treatments.

Personalis is uniquely positioned to capture disproportionate growth in the rapidly expanding MRD market through its clinically validated ultrasensitive technology, which detects cancer recurrence at single-digit parts-per-million levels—a sensitivity threshold that competitors cannot match and that is becoming a clinical necessity rather than a technical advantage. The company's recent Medicare coverage expansions for immunotherapy monitoring in late-stage solid tumors and neoadjuvant therapy monitoring in breast cancer represent critical inflection points that will drive immediate reimbursement acceleration, particularly as these indications cover large patient populations with high unmet needs for real-time treatment response monitoring. These coverage wins are not isolated events but validate the core thesis that NeXT Personal's ability to distinguish true disease burden from pseudoprogression in immunotherapy settings and detect early molecular response in neoadjuvant scenarios addresses fundamental limitations of current standard-of-care diagnostics, creating a durable moat that will support ASP expansion and margin recovery as volume shifts from unreimbursed to reimbursed testing.
The biopharma MRD partnership pipeline is demonstrating strong conversion momentum that remains underappreciated by the market, with committed trials expected to drive the majority of the $20 million to $21 million in full-year biopharma MRD revenue in the second half of 2026, supported by a growing backlog of prospective projects extending beyond 12 months that provides multi-year visibility. Unlike transient diagnostic sales, biopharma MRD engagements are inherently sticky due to the integration of NeXT Personal into clinical trial protocols as a primary endpoint biomarker, creating predictable, multi-year revenue streams as large oncology trials progress through enrollment and follow-up phases. This structural shift toward biopharma adoption is being driven by the irreplaceable need for high-resolution tools to de-risk next-generation therapies, a trend that will persist regardless of near-term reimbursement turbulence and positions Personalis as an indispensable partner in oncology drug development rather than merely a test vendor.
Clinical adoption metrics reveal a powerful inflection point in physician behavior and market expansion that transcends seasonal variability, with over 1,000 ordering physicians in Q1 2026 representing not just geographic breadth but deepening penetration within existing accounts, where retention exceeds 98% and physicians are progressively increasing test utilization as they build confidence in the technology's clinical utility. The real-world evidence showing 40% of positive detections occur in the ultrasensitive range below 100 parts per million across 14 cancer types provides irrefutable proof that conventional MRD tests are missing critical early recurrence signals, creating a self-reinforcing cycle where physicians who adopt NeXT Personal for its sensitivity become advocates who drive broader adoption within their networks—a dynamic that is particularly potent in community oncology settings where word-of-mouth validation outweighs traditional sales efforts and supports sustainable volume growth toward the 43,000 to 45,000 test annual target.
The company's strategic investment in the Variant Tracker module represents a hidden catalyst that extends NeXT Personal beyond static MRD detection into dynamic tumor evolution monitoring, addressing a critical unmet need in precision oncology by enabling physicians to track resistance variant emergence and therapy-induced biological changes in real time—capabilities that directly support adaptive treatment strategies and are increasingly valued in both clinical and biopharma contexts. Early positive feedback on this feature, combined with its presentation at ASCO, suggests it will become a key differentiator that commands premium pricing and expands the total addressable market into therapy monitoring and resistance prediction, areas where current competitors lack comparable functionality and where reimbursement pathways are likely to emerge faster due to clear health economic benefits in avoiding ineffective treatments.

▼ Bear case

Personalis faces significant near-term margin pressure and cash burn that the market may be underestimating due to the intentional but prolonged period of gross margin depression as the company scales clinical volume ahead of reimbursement, with Q1 gross margin at just 1.8% and the company guiding for a full-year range of 15% to 20%—a level that remains structurally challenged given the high fixed costs of its whole-genome sequencing platform and the ongoing investment burden of funding pivotal clinical studies to secure additional Medicare indications. The reliance on future reimbursement coverage to drive margin expansion creates execution risk, as MolDX review timelines are variable and subject to evidentiary standards that may delay coverage for key indications like colorectal cancer surveillance despite strong preliminary data, leaving the company vulnerable to prolonged periods of operating at cash-negative levels while waiting for payer adoption to catch up with clinical validation.
The biopharma MRD revenue pipeline, while growing, remains heavily dependent on a limited number of large pharmaceutical partners and is subject to the inherent volatility of clinical trial initiation and enrollment timelines, with the company acknowledging that the majority of its $20 million to $21 million full-year target is back-end loaded into the second half of 2026—creating significant quarterly revenue lumpiness and execution risk if any major trial experiences delays or modifications in scope. Furthermore, the growing competition from tumor-naïve approaches, exemplified by Guardant's Reveal gaining traction in Tempus's portfolio, threatens to erode Personalis's dominance in the biopharma MRD space as sponsors may opt for simpler, less expensive solutions for certain trial designs where ultra-high sensitivity is not deemed critical, thereby capping the upside of its technological lead and pressuring ASPs in a segment that was expected to be a high-margin growth engine.
Clinical adoption growth, while impressive on a percentage basis, is starting from a very low base and may be overstated in terms of sustainable market penetration, as the company's physician retention metrics do not distinguish between active, high-frequency users and those who order tests sporadically or for niche patient populations, raising concerns about whether the 98% retention rate reflects true clinical integration or merely occasional use that does not translate to reliable, recurring revenue. Additionally, the company's strategy of avoiding incentivization of reimbursed indications to maintain broad oncologist relationships may slow the critical shift toward higher-margin testing, as physicians treating diverse cancer types have little financial motivation to prioritize breast or lung cancer surveillance tests when reimbursement is uncertain or absent for other indications, potentially prolonging the period where volume growth comes primarily from unreimbursed tests that dilute margins without contributing to near-term profitability.
Personalis operates in a market where its technological advantage in ultrasensitivity may be increasingly challenged by emerging competitors developing alternative methodologies or by the potential commoditization of MRD testing as payers and providers begin to question whether the incremental clinical value of single-digit parts-per-million detection justifies the significant cost premium over existing assays, particularly if reimbursement policies fail to evolve rapidly enough to support widespread adoption of the most sensitive technologies. The company's customer concentration risk, coupled with its reliance on a single major distribution partner (Tempus) for the majority of its clinical volume, creates vulnerability to shifts in partnership dynamics or pricing negotiations that could disproportionately impact its access to key physician networks and limit its ability to independently drive adoption, especially as Tempus continues to expand its own tumor-naïve MRD offerings that may compete directly with Personalis's core technology.

Personalis faces significant near-term margin pressure and cash burn that the market may be underestimating due to the intentional but prolonged period of gross margin depression as the company scales clinical volume ahead of reimbursement, with Q1 gross margin at just 1.8% and the company guiding for a full-year range of 15% to 20%—a level that remains structurally challenged given the high fixed costs of its whole-genome sequencing platform and the ongoing investment burden of funding pivotal clinical studies to secure additional Medicare indications. The reliance on future reimbursement coverage to drive margin expansion creates execution risk, as MolDX review timelines are variable and subject to evidentiary standards that may delay coverage for key indications like colorectal cancer surveillance despite strong preliminary data, leaving the company vulnerable to prolonged periods of operating at cash-negative levels while waiting for payer adoption to catch up with clinical validation.
The biopharma MRD revenue pipeline, while growing, remains heavily dependent on a limited number of large pharmaceutical partners and is subject to the inherent volatility of clinical trial initiation and enrollment timelines, with the company acknowledging that the majority of its $20 million to $21 million full-year target is back-end loaded into the second half of 2026—creating significant quarterly revenue lumpiness and execution risk if any major trial experiences delays or modifications in scope. Furthermore, the growing competition from tumor-naïve approaches, exemplified by Guardant's Reveal gaining traction in Tempus's portfolio, threatens to erode Personalis's dominance in the biopharma MRD space as sponsors may opt for simpler, less expensive solutions for certain trial designs where ultra-high sensitivity is not deemed critical, thereby capping the upside of its technological lead and pressuring ASPs in a segment that was expected to be a high-margin growth engine.
Clinical adoption growth, while impressive on a percentage basis, is starting from a very low base and may be overstated in terms of sustainable market penetration, as the company's physician retention metrics do not distinguish between active, high-frequency users and those who order tests sporadically or for niche patient populations, raising concerns about whether the 98% retention rate reflects true clinical integration or merely occasional use that does not translate to reliable, recurring revenue. Additionally, the company's strategy of avoiding incentivization of reimbursed indications to maintain broad oncologist relationships may slow the critical shift toward higher-margin testing, as physicians treating diverse cancer types have little financial motivation to prioritize breast or lung cancer surveillance tests when reimbursement is uncertain or absent for other indications, potentially prolonging the period where volume growth comes primarily from unreimbursed tests that dilute margins without contributing to near-term profitability.
Personalis operates in a market where its technological advantage in ultrasensitivity may be increasingly challenged by emerging competitors developing alternative methodologies or by the potential commoditization of MRD testing as payers and providers begin to question whether the incremental clinical value of single-digit parts-per-million detection justifies the significant cost premium over existing assays, particularly if reimbursement policies fail to evolve rapidly enough to support widespread adoption of the most sensitive technologies. The company's customer concentration risk, coupled with its reliance on a single major distribution partner (Tempus) for the majority of its clinical volume, creates vulnerability to shifts in partnership dynamics or pricing negotiations that could disproportionately impact its access to key physician networks and limit its ability to independently drive adoption, especially as Tempus continues to expand its own tumor-naïve MRD offerings that may compete directly with Personalis's core technology.

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password